Evidence map›Paper›PMID 20518060›Full record

ArticleBiotechnology journal2010

Viral transformation for production of personalized type I interferons.

Dongsheng Xu, Luwen Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dongsheng XuSchool of Biological Sciences, University of Nebraska, Lincoln, NE, USA.
Luwen Zhang

Funding

Virology and Smallpox VaccinationsU54AI057160 · NIAID · WASHINGTON UNIVERSITY · PI BULLER, ROBERT MARK · 2003 to 2013
$80.9M
VIRAL SHUTOFF OF HOST TRANSCRIPTION--PBCV-1 INFECTEDP20RR015635 · NCRR · UNIVERSITY OF NEBRASKA LINCOLN · PI ZHENG, JIALIN CHARLES · 2000 to 2009
$22.1M
Oncogenic properties of interferon regulatory factor 7R01CA108951 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI ZHANG, LUWEN · 2005 to 2009
$1.2M
Modulation of Apoptosis by IRF-4 in EBV transformationR01CA138213 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI ZHANG, LUWEN · 2009 to 2010
$546k
Interferon Regulatory Factor 7 and NPCR21AI059132 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI ZHANG, LUWEN · 2005 to 2006
$394k
NCI NIH HHS CA108951NCI NIH HHS R01 CA108951NCI NIH HHS R01 CA138213NCRR NIH HHS P20 RR015635NCRR NIH HHS P20RR15635NIAID NIH HHS AI59132NIAID NIH HHS R21 AI059132NIAID NIH HHS U54 AI057160NIAID NIH HHS U54AI057160
6 · The paper itself

Abstract

Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of "personalized" IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.

Indexed as

Cell Transformation, ViralBiotechnologyCell Culture TechniquesCell Line, TransformedHerpesvirus 4, HumanHumansInterferon Type ILeukocytes, MononuclearPrecision MedicineInterferon Type I

Identifiers

PMID20518060
PMCPMC3023146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.